Ohta N, Brush M, Jacobs J W
Hitachi Chemical Research Center, Irvine, CA 92715.
Thromb Haemost. 1994 Dec;72(6):825-30.
Antistasin, isolated from the Mexican leech, is a 119 amino acid protein which is a selective and potent inhibitor of coagulation Factor Xa. Previous studies indicated that an arginine residue located at position 34 of the inhibitor was cleaved by Factor Xa during the inhibition reaction. To evaluate this residue as the reactive site of antistasin, and to define shorter fragments of antistasin displaying Factor Xa-inhibitory activity, a series of peptides were synthesized corresponding to amino acids 27-49 of the inhibitor. The most potent peptide synthesized was a disulfide-bridged, 19 amino acid peptide, ATS29-47, which inhibited Factor Xa with a Ki = 35 nM, and increased plasma clotting times by over 4-fold at a concentration of 33 uM. Reduction or sulfation of the cysteine residues in ATS29-47 reduced Factor Xa inhibitory activity by over 95%. Peptides as short as seven residues corresponding to position 33-39 of antistasin displayed Factor Xa inhibitory activity. The peptides did not inhibit thrombin or trypsin at concentrations 1000-fold higher than used in Factor Xa assays. The shortest peptide displaying anticoagulant activity in human plasma was the disulfide-bridged peptide, D-Arg-Cys-Arg-Val-His-Cys-Pro, which increased clotting times by 50% at micromolar concentrations. These results demonstrate that antistasin-related peptide sequences can serve as model structures for the development of novel, low molecular weight anticoagulants.
抗凝血酶抑制素是从墨西哥水蛭中分离出来的一种由119个氨基酸组成的蛋白质,它是凝血因子Xa的一种选择性强效抑制剂。先前的研究表明,在抑制反应过程中,抑制剂第34位的精氨酸残基会被因子Xa切割。为了评估该残基作为抗凝血酶抑制素的反应位点,并确定显示因子Xa抑制活性的抗凝血酶抑制素更短片段,合成了一系列与抑制剂第27 - 49位氨基酸相对应的肽段。合成的最有效肽段是一种二硫键连接的19个氨基酸的肽段,ATS29 - 47,它抑制因子Xa的Ki值为35 nM,在浓度为33 μM时可使血浆凝血时间延长4倍以上。ATS29 - 47中半胱氨酸残基的还原或硫酸化使因子Xa抑制活性降低了95%以上。与抗凝血酶抑制素第33 - 39位相对应的短至七个残基的肽段显示出因子Xa抑制活性。在比用于因子Xa检测的浓度高1000倍的情况下,这些肽段不抑制凝血酶或胰蛋白酶。在人血浆中显示抗凝血活性的最短肽段是二硫键连接的肽段D - Arg - Cys - Arg - Val - His - Cys - Pro,它在微摩尔浓度下可使凝血时间延长50%。这些结果表明,与抗凝血酶抑制素相关的肽序列可作为开发新型低分子量抗凝血剂的模型结构。